Ferumoxytol于2009年获得美国食品和药物管理局（FDA）批准，是一种静脉注射氧化铁纳米颗粒，被授权用于治疗慢性肾病（CKD）和终末期肾病（ESRD）缺铁症。凭借其优异的磁性能、催化活性和免疫活性以及良好的生物相容性和安全性，ferumoxytol在各种生物医学诊断和治疗中获得了显着的认可。与该主题的大多数现有综述不同，这篇综述主要关注费鲁莫托在疾病治疗方面的最新临床和临床前进展，涵盖贫血、癌症、感染性炎症性疾病、再生医学应用、神经调节磁刺激等。讨论了与 ferumoxytol 生物效应相关的发现机制，包括其磁性、催化和免疫调节特性。最后，对基于阿莫西托的纳米药物的治疗和应用进行了总结和展望。本文受版权保护。保留所有权利。本文受版权保护。版权所有。

Ferumoxytol, approved by the U.S. Food and Drug Administration (FDA) in 2009, is one of intravenous iron oxide nanoparticle authorized for the treatment of iron deficiency in chronic kidney disease (CKD) and end-stage renal disease (ESRD). With its exceptional magnetic properties, catalytic activity, and immune activity, as well as good biocompatibility and safety, ferumoxytol has gained significant recognition in various biomedical diagnoses and treatments. Unlike most existing reviews on this topic, this review primarily focuses on the recent clinical and preclinical advances of ferumoxytol in disease treatment, spanning anemia, cancer, infectious inflammatory diseases, regenerative medicine application, magnetic stimulation for neural modulation, etc. Additionally, the newly discovered mechanisms associated with the biological effects of ferumoxytol are discussed, including its magnetic, catalytic, and immunomodulatory properties. Finally, the summary and future prospects concerning the treatment and application of ferumoxytol-based nanotherapeutics are presented. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.